Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 1
2010 1
2011 3
2012 3
2013 1
2014 1
2017 2
2019 1
2020 3
2021 3
2022 3
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages.
Obradovic A, Chowdhury N, Haake SM, Ager C, Wang V, Vlahos L, Guo XV, Aggen DH, Rathmell WK, Jonasch E, Johnson JE, Roth M, Beckermann KE, Rini BI, McKiernan J, Califano A, Drake CG. Obradovic A, et al. Among authors: aggen dh. Cell. 2021 May 27;184(11):2988-3005.e16. doi: 10.1016/j.cell.2021.04.038. Epub 2021 May 20. Cell. 2021. PMID: 34019793 Free PMC article.
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.
Lee CH, Voss MH, Carlo MI, Chen YB, Zucker M, Knezevic A, Lefkowitz RA, Shapnik N, Dadoun C, Reznik E, Shah NJ, Owens CN, McHugh DJ, Aggen DH, Laccetti AL, Kotecha R, Feldman DR, Motzer RJ. Lee CH, et al. Among authors: aggen dh. J Clin Oncol. 2022 Jul 20;40(21):2333-2341. doi: 10.1200/JCO.21.01944. Epub 2022 Mar 17. J Clin Oncol. 2022. PMID: 35298296 Free PMC article. Clinical Trial.
Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses.
Aggen DH, Ager CR, Obradovic AZ, Chowdhury N, Ghasemzadeh A, Mao W, Chaimowitz MG, Lopez-Bujanda ZA, Spina CS, Hawley JE, Dallos MC, Zhang C, Wang V, Li H, Guo XV, Drake CG. Aggen DH, et al. Clin Cancer Res. 2021 Jan 15;27(2):608-621. doi: 10.1158/1078-0432.CCR-20-1610. Epub 2020 Nov 4. Clin Cancer Res. 2021. PMID: 33148676 Free PMC article.
Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
Guercio BJ, Sarfaty M, Teo MY, Ratna N, Duzgol C, Funt SA, Lee CH, Aggen DH, Regazzi AM, Chen Z, Lattanzi M, Al-Ahmadie HA, Brannon AR, Shah R, Chu C, Lenis AT, Pietzak E, Bochner BH, Berger MF, Solit DB, Rosenberg JE, Bajorin DF, Iyer G. Guercio BJ, et al. Among authors: aggen dh. Clin Cancer Res. 2023 Nov 14;29(22):4586-4595. doi: 10.1158/1078-0432.CCR-23-1283. Clin Cancer Res. 2023. PMID: 37682528
Considerations for treatment duration in responders to immune checkpoint inhibitors.
Marron TU, Ryan AE, Reddy SM, Kaczanowska S, Younis RH, Thakkar D, Zhang J, Bartkowiak T, Howard R, Anderson KG, Olson D, Naqash AR, Patel RB, Sachdev E, Rodriguez-Ruiz ME, Sheffer M, Church S, Fuhrman C, Overacre-Delgoffe A, Nguyen R, Florou V, Thaxton JE, Aggen DH, Guerriero JL. Marron TU, et al. Among authors: aggen dh. J Immunother Cancer. 2021 Mar;9(3):e001901. doi: 10.1136/jitc-2020-001901. J Immunother Cancer. 2021. PMID: 33653801 Free PMC article. Review.
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.
Funt SA, Lattanzi M, Whiting K, Al-Ahmadie H, Quinlan C, Teo MY, Lee CH, Aggen D, Zimmerman D, McHugh D, Apollo A, Durdin TD, Truong H, Kamradt J, Khalil M, Lash B, Ostrovnaya I, McCoy AS, Hettich G, Regazzi A, Jihad M, Ratna N, Boswell A, Francese K, Yang Y, Folefac E, Herr HW, Donat SM, Pietzak E, Cha EK, Donahue TF, Goh AC, Huang WC, Bajorin DF, Iyer G, Bochner BH, Balar AV, Mortazavi A, Rosenberg JE. Funt SA, et al. Among authors: aggen d. J Clin Oncol. 2022 Apr 20;40(12):1312-1322. doi: 10.1200/JCO.21.01485. Epub 2022 Jan 28. J Clin Oncol. 2022. PMID: 35089812 Free PMC article. Clinical Trial.
A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer.
Kotecha RR, Doshi SD, Knezevic A, Chaim J, Chen Y, Jacobi R, Zucker M, Reznik E, McHugh D, Shah NJ, Feld E, Aggen DH, Rafelson W, Xiao H, Carlo MI, Feldman DR, Lee CH, Motzer RJ, Voss MH. Kotecha RR, et al. Among authors: aggen dh. Eur Urol Oncol. 2023 Nov 7:S2588-9311(23)00229-8. doi: 10.1016/j.euo.2023.10.017. Online ahead of print. Eur Urol Oncol. 2023. PMID: 37945488
23 results